None listed
Conditions
Interventions
Intervention1: NAD+: Formulation- Capsules
Route of Administration- Oral
A total of four capsules will be administered as a single dose after breakfast.
Duration -10 days
NAD+ Arm: Each capsule co
Sponsors
Medstar Specialist Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult male/female healthy participants aged 18 to 65 years; 2. Participants with Body Mass Index (BMI) between 18.5 and 24.99 kg/m2; 3. Participants who are willing to provide written Informed Consent for participating in the study; 4. Participants who are able to follow verbal and written study directions; 5. Participants willing to abstain from consumption of foods, medications, or dietary supplements containing the investigational drug (or related compounds) from 3 days prior the start of the study and throughout its duration.
Exclusion criteria
Exclusion criteria: 1. Participants with history of allergic reactions or hypersensitivity to the investigational drug or related supplements; 2. Participants having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator; 3. Participants with any acute illness diagnosed within 3 months before screening; 4. Participants with a medical history or active diagnosis of chronic diseases or conditions affecting the urinary, cardiovascular, neuroendocrine (including diabetes), immune, central nervous, hematopoietic, gastrointestinal, hepatic, or visual systems, hereditary diseases, or other significant systemic disorders, as well as those with acute infectious diseases within 28 days prior to the study, known allergies or positive test results for sexually transmitted infections such as HIV, hepatitis B, hepatitis C, or syphilis; 5. Female participants with positive result for urinary beta human chorionic gonadotropin or gestation period or breastfeeding; 6. Participants who smoked more than 2 cigarettes a day within 6 months before screening 7. Participants unwilling to refrain from high intensity physical activity for a minimum of 3 days before start of the study and throughout its duration. 8.Participants who have a history of recent injuries or is hospitalized within the past 3 months
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters will be assessed by determining the following: Peak Plasma Concentration (Cmax) Time to peak drug concentration (Tmax), Area under curve (AUC) and half lifeTimepoint: Time frame: 0h, 0.5h, 1.0h, 1.5h, 2.0h, 3.0h, 4.0h, 6.0h, 8.0h, 12.0h, and 24.0h | — |
Primary
| Measure | Time frame |
|---|---|
| NAD+ concentrations will be assessed by determining the following: Whole blood concentration Plasma concentration Erythrocyte concentrationTimepoint: Time frame: 0h, 0.5h, 1.0h, 1.5h, 2.0h, 3.0h, 4.0h, 6.0h, 8.0h, 12.0h, and 24.0h | — |
Countries
India
Contacts
Public ContactDr Chikkalingaiah Siddegowda
Medstar Speciality Hospital
Outcome results
None listed